Multi-omics in Oncology: Discovering Novel Biomarkers and Targets

A special issue of Biology (ISSN 2079-7737). This special issue belongs to the section "Cancer Biology".

Deadline for manuscript submissions: 31 October 2024 | Viewed by 1841

Special Issue Editor

Special Issue Information

Dear Colleagues,

Cancer is a complex ecosystem shaped by tumor cell heterogeneity, interactions with the tumor microenvironment, and spatiotemporal dynamics. Single-cell assays have revolutionized oncology research, allowing for high-resolution mapping of the tumor immune landscape. Technological advancements have also allowed the measurement of diverse histological patterns, such as genomics, epigenomics, transcriptomics, proteomics, metabolomics, and imaging phenotypes. Integration of single-cell and bulk-level multi-omics data from preclinical models and patient samples offers valuable insights into the functioning of the tumor immune ecosystem and responses to therapy, leading to improved biomarkers and treatments.

Multi-omics-based subtype analysis, combining proteomic, phosphorylated proteomic, and genomic analyses of cancer tissues, could potentially unravel the interconnectedness between cancer signaling and crucial metabolic pathways. Topics of this Special Issue include:

  • Post-translational modifications in cancer biology;
  • Molecular tumor pathology and classification;
  • Cancer biomarkers: screening and diagnosis;
  • Tumor microenvironment.

Dr. Chia-Jung Li
Guest Editor

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Biology is an international peer-reviewed open access monthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2700 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • multi-omics
  • cancer signaling
  • biomarkers

Published Papers (1 paper)

Order results
Result details
Select all
Export citation of selected articles as:

Review

20 pages, 1031 KiB  
Review
Current Research on Molecular Biomarkers for Colorectal Cancer in Stool Samples
by Patricio Órdenes, Claudio Carril Pardo, Roberto Elizondo-Vega and Karina Oyarce
Biology 2024, 13(1), 15; https://doi.org/10.3390/biology13010015 - 27 Dec 2023
Viewed by 1391
Abstract
Colorectal cancer (CRC) is one of the most diagnosed cancers worldwide, with a high incidence and mortality rate when diagnosed late. Currently, the methods used in healthcare to diagnose CRC are the fecal occult blood test, flexible sigmoidoscopy, and colonoscopy. However, the lack [...] Read more.
Colorectal cancer (CRC) is one of the most diagnosed cancers worldwide, with a high incidence and mortality rate when diagnosed late. Currently, the methods used in healthcare to diagnose CRC are the fecal occult blood test, flexible sigmoidoscopy, and colonoscopy. However, the lack of sensitivity and specificity and low population adherence are driving the need to implement other technologies that can identify biomarkers that not only help with early CRC detection but allow for the selection of more personalized treatment options. In this regard, the implementation of omics technologies, which can screen large pools of biological molecules, coupled with molecular validation, stands out as a promising tool for the discovery of new biomarkers from biopsied tissues or body fluids. This review delves into the current state of the art in the identification of novel CRC biomarkers that can distinguish cancerous tissue, specifically from fecal samples, as this could be the least invasive approach. Full article
(This article belongs to the Special Issue Multi-omics in Oncology: Discovering Novel Biomarkers and Targets)
Show Figures

Figure 1

Back to TopTop